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Abstract 
Background: In Italy, the nsLTP (Pru p 3) has been identified as the most frequent cause of food allergy and anaphy-
laxis. In order to estimate the risk assessment in peach allergy, we investigated the presence of correlations between 
the levels of sIgE to Pru p 3 with the severity of the clinical symptoms in two Pru p 3 positive populations from two 
different areas of Italy.
Methods: 133 consecutively Pru p 3 positive patients were recruited from South Italy, where the prevalence of PR-10 
and profilin sensitization is low, and from North-East Italy, where the sensitization to pathogenesis related protein -10 
(PR-10) and profilin is higher. Skin prick test (SPT) to peach extract and sIgE to peach panallergens were performed.
Results: All 133 patients were positive to SPT to peach extract and to sIgE to Pru p 3. The North-East population was 
simultaneously positive to Pru p 1 (42.8 %) and Pru p 4 (12.7 %), while no Southern patients were positive to PR-10 
or to profilin. A significant difference in the levels of sIgE to Pru p 3 was found only in South Italy Pru p 3 + patients 
vs. asymptomatic patients (p = 0.01) and in mild reactions vs. severe reactions (p = 0.0008). In South Italy patients, it 
was also found a significant correlation between the severity of the clinical reaction and the levels of sIgE to Pru p 3 
(p = 0.001).
Conclusion: Level of sIgE to Pru p 3 indicates the possibility of development a severe food allergic reaction. Pru p 3 
positive patients from different geographical areas and with different co-sensitizations to Pru p 1 and/or Pru p 4 could 
have a different risk assessment in peach allergy.
Keywords: nsLTP, Peach allergy, sIgE to Pru p 3, Anaphylactic biomarker, Risk assessment, Co-sensitization, Molecular 
allergy based diagnosis
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Background
The possibility to predict, by in  vitro approaches, the 
development of symptoms related to food allergy (FA) 
has been studied by different research groups and several 
data have been published focusing on this point. Interest-
ingly, some results have demonstrated that the levels of 
specific IgE (sIgE) for food allergens can be considered a 
reliable marker of a positive “in vivo” challenge test. [1–
3]. Currently, the risk assessment of FA can be predicted 
in a more accurate way since the development of the 
molecular allergy based diagnosis, although it’s still not 
possible to distinguish between patients who are asymp-
tomatic from those symptomatic.
In FA, the molecular allergy based diagnosis has the 
peculiarity of identify different type of sensitizations 
depending on the geographical area. For example, it has 
been shown that the sensitization to the panallergen 
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non-specific lipid transfer protein (nsLTP) increases 
from North Europe to the Mediterranean area, while 
the sensitization to the pathogenesis related protein-10 
(PR-10) increases in the opposite direction. By con-
trast, the frequency of sensitization to profilin is almost 
invariable.
Several studies showed that Pru p 3, the peach nsLTP, 
is the more frequent cause of food-induced allergy and 
anaphylaxis in Italy [4–6]. The clinical manifestations of 
nsLTP sensitization range from those of minor entity, like 
contact itch or oral allergic syndrome (OAS), to anaphy-
lactic shock. [7].
The sensitization to this heat and proteolytic digestion 
resistant protein is potentially very dangerous [8]. Cross 
reactions between peach nsLTP and nsLTP from other 
foods, have been described with other members of the 
Rosaceae family, seed, nuts, cereals, and other foods from 
plant origin [9–19].
The relationship between the levels of sIgE, the sever-
ity of the clinical reactions and the presence of symptoms 
with foods containing nsLTP different from peach, is 
presently controversial [20–23].
In consideration of the potential hazard of the sensiti-
zation to Pru p 3, it is evident how important is to iden-
tify a biomarker able to predict both the severity of an 
allergic reaction and the potential cross reactions with 
other nsLTP foods.
The aim of this study was to investigate a possible cor-
relation between an anaphylactic biomarker, such as sIgE 
to Pru p 3, with the severity of symptoms in two Pru p 3 
sensitized populations from different geographical areas 
of Italy. In addition, we performed the ROC curve analy-
sis of the sIgE to Pru p 3 in order to identify patients at a 
higher risk of anaphylaxis and compare our results with 
the data published in literature.
Methods
Patients
133 consecutively allergic patients who attended the 
observation were recruited. A common selection criteria 
was used in all participating center: (a) clear history of an 
allergic reaction after being in contact with/or after the 
consumption of peach, (b) skin prick test (SPT) positive 
to peach extract, (c) positive sIgE to Pru p 3, (d) positive 
oral open food challenge or in case the challenge could 
not been performed, a well-documented severe allergy 
had been exhibited, e) patients positive to SPT to peach 
and to sIgE to Pru p 3 but asymptomatic. None of the 
patients were under oral corticosteroid or antihistamine.
All 71 patients who attended the outpatient Allergy 
Unit of C.N.R. and Buccheri La Ferla Hospital were born 
and live in Palermo (South Italy). All 62 patients who 
attended the outpatient Allergy Unit of Santa Maria degli 
Angeli Hospital were born and live in Pordenone (North-
East, Italy).
Patients were divided into four groups based on sever-
ity of symptoms: asymptomatic, OAS, mild systemic 
reactions (Mueller classification grade 1–2), and severe 
systemic reactions (Mueller classification grade 3–4) 
(Table 1) [24].
Skin prick tests
SPTs to peach extract (ALK-Abello, Milan, Italy) were 
performed consecutively by the same investigator in 
the South population and by another investigator in the 
North-East population, on the volar surface of the fore-
arm by using a standard l mm tip lancet, according to the 
recommendations of the European Academy of Allergy 
and Clinical Immunology group. Histamine hydrochlo-
ride (10  mg/mL) and saline (ALK-Abello, Milan, Italy), 
respectively, were used as positive and negative controls.
The SPT results were considered positive if the differ-
ence between the mean diameter of the wheal and the 
negative control was at least of 3 mm.
sIgE dosage
sIgE anti-rPru p 1, anti-rPru p 3, and anti-rPru p 4 
were consecutively determined using the Immuno-
CAP system (Thermofisher/Phadia Diagnostics, Upp-
sala, Sweden). Results were expressed in kUA/L and a 
value >0.15 kUA/L was considered positive.
All serum samples were consecutively analysis by both 
Buccheri La Ferla and Maria degli Angeli laboratories. 
The calibration test was done when the ImmunoCAP 250 
required. Every day, new reagents were used due to the 
high number of samples analysed by both laboratories. 
During every single session, two control curves and one 
quality control (given by Thermofisher/Phadia Diagnos-
tics) were performed. In addition, measurements of sIgE 
to peach and to Pru p 3 were done using a “house con-
trol” (obtained from a serum pool frozen at −80 °C).
Table 1 Demographic and clinical characteristics of sensi-
tized peach patients from North-East and South Italy
South Italy North-East Italy
 Patients (n) 71 62
 Sex (f/m) 41/30 34/28
 Age (mean, years) 25.7 38.03
 Clinical manifestation (n)
 Asymptomatic 5 13
 OAS 7 28
 Mild reactions 40 17
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Both laboratories have been participated to exter-
nal VEQ specific allergy programs: Buccheri La Ferla 
laboratory has been participated to the Sicilian Region 
CRQ and the laboratory from Pordenone, to the 
NEQAS UK.
To be sure the results were reproducible, all 133 serum 
samples were analysed by Buccheri La Ferla laboratory, 
during a single session, using the same batch of reagents.
Oral food challenge
Patients with OAS reintroduced peaches under our 
supervision and experienced local symptoms of OAS. 
In view of the observational nature of the study and of 
the fear of several patients of a possibly severe adverse 
reaction, patients with systemic reactions were not chal-
lenged because of documented severe peach allergy [25].
The study was performed with the approval of the 
ethics committee of Policlinico—Giaccone Hospital—
Palermo Italy (7/2013–12.06.2013) and was in agreement 
with the Helsinki Declaration. Written consent form was 
obtained from the patients.
Statistical methods
The association between levels of sIgE to Pru p 3 in 
asymptomatic vs. symptomatic patients with local and 
systemic reactions were analyzed by Mann–Whitney test.
The ROC analysis was carried out to determine the 
optimal cut-off value of sIgE to Pru p 3 to distinguish 
asymptomatic from symptomatic patients both in South 
and North-East Italian populations.
Correlations between sIgE levels and symptom sever-
ity were assessed using Spearman rank correlation 
(rho). In addition, the odds ratio of sIgE levels to Pru 
p 3 was calculated to assess the risk of severe reac-
tions. The latest test was not done in the North-East 
group due to the low number of patients with severe 
reactions.
Medcalc 11.4.4.0 was used for the statistical analyses. A 
p value of <0.05 was considered significant.
Results
All South and North-East Italian patients were positive 
(mean diameter > 3 mm) to SPT to peach extract and to 
sIgE to Pru p 3. The sensitization to other panallergens 
differs according to the geographical area: the North-
East population was simultaneously positive to Pru p 1 
(42.8 %) and Pru p 4 (12.7 %), while no Southern patients 
were positive to PR-10 or to profilin (Table 2).
The levels of sIgE to Pru p 3 from the two populations 
are shown in Fig. 1.
In the South population, it was found a significant 
difference in the levels of sIgE to Pru p 3 between all 
symptomatic patients (OAS, mild, and severe systemic 
reactions) vs. asymptomatic patients (p  =  0.01), and 
between patients with mild systemic reactions com-
pare with patients with severe systemic reactions 
(p = 0.0008). On the other hand, in the North-East pop-
ulation, not significant differences were found in the lev-
els of sIgE to Pru p 3 between symptomatic (OAS, mild, 
and severe systemic reactions) vs. asymptomatic patients 
(p = 0.08) and between patients with mild systemic reac-
tions compared with patients with severe systemic reac-
tions (p = 0.09).
Interestingly, in the South population was found a cor-
relation between the severity of the clinical reactions and 
the levels of sIgE to Pru p 3 (Spearman’s test  =  0.366; 
p = 0.001). Unfortunately, in the North-East population, 
not correlation test was done due to the low number of 
patients with severe allergic reactions.
The ROC curve analysis from all South Pru p 3 positive 
patients identified a value of sIgE to
Pru p 3 of 2.87  kUA/L as the best value discriminat-
ing asymptomatic from symptomatic (OAS, mild, and 
severe systemic reactions) patients [sensitivity 91.04  % 
(95 % CI 81.5–96.6); specificity 75 % (95 % CI 19.4–99.4); 
LR + 3.64 (95 % CI 2.1–6.4); Fig. 2].
A value of sIgE to Pru p 3 of 5.87 kUA/L has a sensi-
tivity of 67.16 % (95 % CI 54.6–78.2) and a specificity of 
100 % (95 % CI 39.8–100.0).
The ROC curve analysis from all North-East Pru p 3 
positive patients identified a value of sIgE to Pru p 3 of 
2.68 kUA/L as the best value that discriminated asympto-
matic from symptomatic (OAS, mild, and severe systemic 
reactions) patients [sensitivity 36.0 % (95 % CI 22.9–50.8); 
specificity 69.2 % (95 % CI 38.6–90.9); LR + 1.17 (95 % CI 
0.7–2.0); Fig. 2].
In the South group, the value of sIgE to Pru p 3 of 
10.2 kUA/L was the best value that discriminated severe 
reactions from other clinical reactions [sensitivity 70.0 % 
(95  % CI 45.7–88.1); specificity 88.9  % (95  % CI 65.3–
98.6); LR + 6.30 (95 % CI 4.5–8.8)]. Due to the low num-
ber of severe reactions in the North-East population, it 
was not possible identify a value of sIgE to Pru p 3 able 
to discriminate severe reactions from other clinical reac-
tions (Fig. 3).
The area under curve (AUC) of symptomatic (OAS, 
mild, and severe systemic reactions) vs. asymptomatic 
Table 2 Difference in  sensitization to  peach allergens 
between the North-East and the South Italian patients
* p < 0.0001
** p = 0.005
Pru p 1 Pru p 4 Pru p 3
 Palermo n = 71 (%) 0* 0** 100
 Pordenone n = 62 (%) 42.8 12.7 100
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patients living in South Italy and North-East Italy were 
0.873 and 0.631 (p  <  0.0001; p  =  0.1116), respectively. 
AUC of patients with clinical severe reaction vs. all other 
reactions were 0.819 and 0.755 (p  <  0.0001; p  =  0.12), 
respectively.
The risk assessment of severe allergic reactions was 
the following: for a value of sIgE to Pru p 3 >7.5 kUA/L, 
the odds ratio 95  % CI was 69 (2.3–2028; p  =  0.01) 
and  >10  kUA/L, the odds ratio 95  % CI was 225 (3.9–
13,114; p = 0.009).
Fig. 1 Levels of sIgE to Pru p 3 in peach allergic patients from South and North-East Italy according to the clinical reactions
Fig. 2 ROC curves for sIgE to Pru p 3 values in all peach allergic patients from South and North-East Italy
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Discussion
For the first time, a study evaluates the usefulness of an 
anaphylactic biomarker in the risk assessment of Pru p 3 
positive patients from different geographical areas of the 
same country.
In this study, we investigated the presence of correla-
tions between the levels of sIgE to Pru p 3 with the sever-
ity of the clinical reactions in a South Italian population 
and compared them, with the results from a Nord-East 
Italian population, where the prevalence of sensitization 
to birch pollen is similar to North Europe.
All patients were assigned to one of the four groups 
according to their clinical manifestations: asymptomatic, 
OAS, mild systemic reactions and severe systemic reac-
tions. We found that levels of sIgE to Pru p 3 (Mann–
Whitney test) in the South population was significantly 
different between asymptomatic vs. symptomatic (OAS, 
mild and severe systemic reactions) Pru p 3 positive 
patients and between patients with mild systemic reac-
tions in comparison to those with severe systemic reac-
tions. Surprising, we could not found any significant 
differences in the levels of sIgE to Pru p 3 (Mann–Whit-
ney test) in none of the groups from North-East Italy.
Few studies have assessed the relationship between the 
levels of sIgE to Pru p 3 and the severity of the clinical 
reactions, and taken all together provided contradictory 
results. Gaier et al. [26] have reported that the presence 
of sIgE to Pru p 3 in peach allergic patients who live in 
a geographical area with a high sensitization to birch 
pollen, may be considered a marker of severe reactions. 
On the other hand, Novembre et al. [21] have not found 
any relations between the levels of sIgE and the severity 
of the clinical reaction in a pediatric population; while 
Pastorello et  al. [23] have found sIgE levels to Pru p 3 
significantly higher in patients with severe OAS than in 
patients with mild OAS. In this study, we found a signifi-
cant correlation between the severity of the clinical reac-
tion and the levels of sIgE to Pru p 3. The differences in 
the results obtained could be attributed to the different 
type of population included in the studies.
An important result of this study was the determina-
tion of a cut-off level for sIgE to Pru p 3 values that can 
better discriminate asymptomatic patients from those 
symptomatic (2.87  kUA/L for the South Italian popula-
tion and 2.69 kUA/L for the North-East population) and 
within this group, identify those patients at a higher risk 
for developing severe allergic reactions.
Pastorello et  al. [23] have identified a cut-off value of 
sIgE to Pru p 3 of 2.69  kUA/L with a lower sensitivity 
63.9  % but similar specificity 75  % that better discrimi-
nated peach-allergic patients at a higher risk for develop-
ing more severe symptoms.
Interestingly, we found a value of sIgE to Pru p 3 higher 
than 10.2  kUA/L (sensitivity almost of 90  %) that was 
present in 70 % of the patients with severe systemic reac-
tions from South Italy. In the North-East group, with the 
same value of sIgE to Pru p 3, we have a higher specific-
ity but a lower sensitivity. However, we cannot exclude 
that these results are probably affected by a bias due to 
the low numbers of patients with severe allergic reactions 
included in this population.
Although it has been shown that panallergens differ 
according to the geographical areas [4–6], up to now, 
nobody has studied the prevalence of peach panallergen 
Fig. 3 ROC curve for sIgE to Pru p 3 values in patients with severe allergic reactions from South and North-East Italy
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in Sicily. The high sensitization to nsLTP and the lower 
prevalence of sensitization to profilin have been previ-
ously reported in a study done with Sicilian and Austrian 
patients allergic to Parietaria judaica [27]. In this regard, 
a study done in allergic patients (Uasuf et al. 2014 unpub-
lished data) to assess the prevalence of panallergens 
in South Italy, has found that in 599 positive molecular 
ImmunoCAP tests performed, the prevalence of profilin 
was 3.6 % and of PR-10 was only 1 %.
The different clinical manifestations present in the two 
Italian populations could be attributed not only to the 
existence of different co-sensitization to the panallergens 
but also to the levels of sIgE to Pru p 3. Therefore, lower 
levels of sIgE to Pru p 3 and the co-existence of positivity 
to Pru p1 and/or Pru p 4 could explain the minor fre-
quency of severe reactions in the North-East patients 
with respect to the South patients, monosensitized 
and with higher level of sIgE to Pru p 3. On a specula-
tive level, this fact supports the hypothesis that patients 
positive to Pru p 3 and simultaneously positive to Pru p 
1 and/or Pru p 4, have a sort of ‘protective’ effect against 
the development of severe symptoms induced by Pru p 
3 [23].
Conclusion
Our results show that the level of an anaphylactic bio-
marker like sIgE to Pru p 3, indicates the possibility of 
development a severe food allergic reaction. In addi-
tion, Pru p 3 positive patients from different geographi-
cal areas and with different co-sensitizations could have a 
different risk assessment in peach allergy.
This study could be a model to extrapolate to other geo-
graphical areas with different co-sensitizations to identify 
probably high risk group in food allergy.
Further studies, including multicentre studies are nec-
essary to confirm and expand these results.
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